NASDAQ
Kyverna Therapeutics, Inc. (KYTX) has a free cash flow growth of -24.09% as of Friday, May 29, 2026. This represents a 2502.05% decrease compared to its 12-month average of -0.93%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.